5-溴-2-羟基-4-甲氧基苯甲醛 | 57543-36-9

• 物质功能分类: 有机原料 - 醛类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 5-溴-2-羟基-4-甲氧基苯甲醛
• 中文别名: 2-羟基-4-甲氧基-5-溴苯甲醛
• 英文名称: 5-bromo-2-hydroxy-4-methoxybenzaldehyde
• 英文别名: 3-bromo-6-hydroxy-4-methoxy-benzaldehyde
• CAS: 57543-36-9
• 化学式: C₈H₇BrO₃
• 分子量: 231.046
• InChiKey: OHSSWZLKWHLYFP-UHFFFAOYSA-N

物化性质

• 熔点：
  63-64 °C(Solv: ethyl acetate (141-78-6); hexane (110-54-3))
• 沸点：
  312.7±37.0 °C(Predicted)
• 密度：
  1.653±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2913000090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H302,H315,H319
• 储存条件：
  室温且干燥

反应信息

• 作为反应物：
  描述：

  5-溴-2-羟基-4-甲氧基苯甲醛 在 硝酸 作用下， 生成 4-bromo-5-methoxy-2-nitrophenol
  参考文献：
  名称：

  Long-Term Therapy using GHB (Sodium Gamma Hydroxybutyrate) for Treatment-Resistant Chronic Alcoholics

  摘要：

  Thirty-five alcohol-dependent patients according to DSM-IV criteria who also met criteria for treatment resistance were treated with doses of gamma hydroxybutyrate (GHB) ranging between 25 and 100 mg/kg/die in an open one-year study. The results show that no patients discontinued the program during the first month of treatment. Sixty percent of these patients successfully completed the protocol; 11.4% showed complete abstinence (full responder patients); 14.3% strongly reduced their alcohol intake (partial responder patients) and 34.3% of the patients were still under treatment after one year. Forty percent of the patients were nonresponders. The retention rate under treatment of the studied sample was statistically higher than that found during the last treatment of the same subjects. No significant differences were found between full responder and partial responder patients regarding changes in clinical features, alcohol intake or social adjustment. Patients still in treatment after one year significantly differed from nonresponder patients on all the variables investigated. A six-times/daily fractionated administration of the GHB dose was the only significant predictor of the retention rate.

  DOI：

  10.1080/02791072.2001.10400478
• 作为产物：
  描述：

  5-溴-2,4-二甲氧基苯甲醛 在 三氯化硼 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以86%的产率得到5-溴-2-羟基-4-甲氧基苯甲醛
  参考文献：
  名称：

  Antiangiogenic versus cytotoxic activity in analogues of aeroplysinin-1

  摘要：

  A series of analogues of the potentially angiogenic inhibitor aeroplysinin-l 1 were synthesized and their in vitro antiangiogenic and cytotoxic activities evaluated. In the case of epoxy ketone 6 and azlactone 36 the relationship sprouting inhibition assayl cytotoxicity in BAE cells was enhanced by one order and two orders of magnitude, respectively, with respect to the reference. These results imply more specific antiangiogenic properties for the synthesized derivatives. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.05.011

文献信息

• Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
  申请人：——

  公开号：US20030083357A1

  公开（公告）日：2003-05-01

  The present invention relates to compounds of Formula (I) which may be useful in the treatment of diseases, such as, metabolic disorders, dyslipidemia and/or hyperchloesterolemia: 1

  本发明涉及Formula (I)的化合物，可能在治疗疾病，如代谢紊乱、血脂异常和/或高胆固醇血症方面有用：
• Heterocyclic derivatives for the treatment of diabetes and other diseases
  申请人：Maxia Pharmaceuticals, Inc.

  公开号：US06515003B1

  公开（公告）日：2003-02-04

  The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, such as osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease.

  本发明涉及某些Formula (I)的取代杂环，这些取代杂环在治疗与脂质和碳水化合物代谢相关的疾病方面很有用，如2型糖尿病、脂肪细胞分化、不受控制的增殖，如淋巴瘤、霍奇金病、白血病、乳腺癌、前列腺癌或一般癌症；以及炎症，如骨关节炎、类风湿关节炎、克罗恩病或炎症性肠病。
• Indolinone compounds as kinase inhibitors
  申请人：Sugen, Inc.

  公开号：US06689806B1

  公开（公告）日：2004-02-10

  The invention relates to certain indolinone compounds, their method of synthesis, and a combinatorial library consisting of the indolinone compounds of the invention. The invention also relates to methods of modulating the function of protein kinases using indolinone compounds of the invention and methods of treating diseases by modulating the function of protein kinases and related signal transduction pathways.

  这项发明涉及某些吲哚酮化合物，它们的合成方法，以及由该发明的吲哚酮化合物组成的组合式文库。该发明还涉及使用该发明的吲哚酮化合物调节蛋白激酶功能的方法，以及通过调节蛋白激酶功能和相关信号转导途径治疗疾病的方法。
• Pt(IV)-catalyzed generation and [4+2]-cycloaddition reactions of o-quinone methides
  作者：Suttipol Radomkit、Pakornwit Sarnpitak、Jumreang Tummatorn、Paratchata Batsomboon、Somsak Ruchirawat、Poonsakdi Ploypradith

  DOI：10.1016/j.tet.2011.03.059

  日期：2011.5

  Novel intermolecular and intramolecular generations of ortho-quinone methides and their formal [4+2]-cycloaddition reactions with olefins catalyzed by PtCl4 and AuCl3 under mild conditions have been developed. Good to excellent yields (up to 99%) and diastereoselectivity (up to >99:1) of the chromans were obtained. PtCl4 was found to be effective and compatible with various functional groups present

  已经开发了新的分子间和分子内生成的邻醌甲基化物及其在温和条件下与PtCl 4和AuCl 3催化的烯烃的正式[4 + 2]-环加成反应。获得了良好的品色（高达99％）和非对映体选择性（高达> 99：1）的苯并二氢吡喃。发现PtCl 4是有效的并且与存在于底物中的各种官能团相容。提出并讨论了其催化循环的机理。
• [EN] 1,4-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND THEIR USE FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS<br/>[FR] DÉRIVÉS DE PYRIDAZINE 1,4-DISUBSTITUÉS ET LEUR UTILISATION POUR LE TRAITEMENT DE PATHOLOGIES LIÉES À UNE DÉFICIENCE EN SMN
  申请人：NOVARTIS AG

  公开号：WO2015017589A1

  公开（公告）日：2015-02-05

  The present invention provides a compound of formula IA or a pharmaceutically acceptable salt thereof; 5 (IA) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种公式IA的化合物或其药用盐；5（IA）一种制造本发明化合物的方法及其治疗用途。本发明进一步提供了一种药物活性剂的组合物和药物组合物。